Assembly Biosciences (NASDAQ:ASMB) Releases Quarterly Earnings Results, Beats Estimates By $2.99 EPS

Assembly Biosciences (NASDAQ:ASMB) announced its earnings results on Thursday. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99, FiscalAI reports. The firm had revenue of $42.47 million for the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%.

Assembly Biosciences Stock Performance

Assembly Biosciences stock traded down $0.01 during trading on Thursday, reaching $27.51. The company had a trading volume of 54,940 shares, compared to its average volume of 100,312. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $39.71. The stock’s 50 day moving average price is $28.23 and its two-hundred day moving average price is $29.55. The firm has a market capitalization of $435.13 million, a price-to-earnings ratio of -5.74 and a beta of 1.11.

Hedge Funds Weigh In On Assembly Biosciences

A number of hedge funds have recently made changes to their positions in ASMB. Bank of America Corp DE grew its stake in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences in the fourth quarter valued at $228,000. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences in the fourth quarter valued at $251,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Assembly Biosciences during the third quarter valued at about $282,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Finally, Mizuho set a $40.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.75.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.